Biomarkers Predictive of Therapeutic Benefit 3

• 2431 · PDF 携带高基因组瘢痕评分（GSS）的早期与转移性非小细胞肺癌（NSCLC）患者的临床结局 Clinical outcome of patients with early stage and metastatic non-small cell lung cancer (NSCLCa) harboring high genomic scarring score (GSS) Panteleimon Konstantoulakis, Georgia Christopoulou, Apostolos Klinakis, Katerina Tsilingiri, Ioannis Vatselas, Natalia Asimakopoulou, Vassilis Georgoulias, Ioannis Pateras, Konstantinos Ntostoglou, Georgios Christodoulopoulos, Athanasios Kotsakis, Vasiliki Anastasopoulou, Dora Hatzidaki, Abdriani Harpidou, Emilia Tsaroucha, Gary Karponi
• 2432 · PDF 白血病中的精准基因组学揭示南亚患者的突变与融合图谱以指导临床决策 Precision genomics in leukemiareveals mutational and fusion landscapes in South Asian patients driving clinical decisions Puja Sinha, Amit Kumar, Shobit Gupta, Rama Chandran, Giulliana Tessarin
• 2433 · PDF BAP1缺失通过TLCD1介导的膜磷脂重塑赋予胆管癌铁死亡抵抗 BAP1 loss confers ferroptosis resistance to cholangiocarcinoma via TLCD1-mediated membrane phospholipid remodeling Yu Zhao, Peyton Classon, Danielle Marie Carlson, Jayla Millender, Irene K. Yan, Sumera Ilyas, Rory L. Smoot, Gregory J. Gores, TUSHAR PATEL, Davide Povero
• 2434 · PDF TP53共突变与RET融合伙伴在RET重排晚期NSCLC中的预后与预测效应 Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Tolulope Adeyelu, Arianna Marinello, Helena Bote-de Cabo, Jamie Feng, Andrea De Giglio, Mariana Brandão, Florian Guisier, Michael Duruisseaux, Christina Falcon, Massimiliano Cani, Francesca Colamartini, Barliz Waissengrin, Isabelle Monnet, Anna Eisert, Emilio Bria, Amin H. Nassar, Ayesha Aijaz, Patricia Iranzo, Colin R. Lindsay, Elizabeth Fabre, Vladmir Cordeiro de Lima, Judith Raimbourg, Laura Mezquita, Nicolas Minatta, Sophie Cousin, Katarzyna Szymczak, Vincent Fallet, Clarisse Audigier-Valette, Helene Doubre, Philippe Rochigneux, Annarita Avanzo, Antonio Calles, Marco Tagliamento, Diego Cortinovis, Balazs Halmos, Nicholas Girard, Andrew Elliott, Jair Bar, Alessio Cortellini, Diana N. Ionescu, Frances A. Shepherd, Fabrice Barlesi, Karen L. Reckamp, David Planchard, Benjamin Besse, Alexander Drilon, Mihaela Aldea
• 2435 · PDF 三级淋巴结构诱导可预测并增强晚期甲状腺癌对famitinib联合PD-L1阻断的响应 Tertiary lymphoid structures induction predicts and enhances response to famitinib plus PD-L1 blockade in advanced thyroid cancer Wei Kou, Yue Che, Qiwu Zhao, Haoran Feng, Zhuoran Liu, Jie Kuang, Weihua Qiu
• 2436 · PDF 基于单细胞空间转录组学的胃癌来源三级淋巴结构评分及其在泛癌种中对免疫治疗响应的验证 Gastric cancer-derived tertiary lymphoid structure score from single-cell spatial transcriptomics with pan-cancer validation for immunotherapy response Wenbo Zhu, Hongru Shen, Huijun Wang, Ben Liu, Xiangchun Li, Kexin Chen
• 2437 · PDF 多发性骨髓瘤中针对BCMA、GPRC5D和CD38靶向治疗的比较性评分框架 A comparative scoring framework for BCMA-, GPRC5D- and CD38-targeted therapies in multiple myeloma Konstantin Chernyshov, Stanislav Kurpe, Maria Kuzmicheva, Kseniia Fede, Sargis Margaryan, Daria Goncharova, Anastasiya Evdokimova, Dmitry Grachev, Oleg Baranov, Polina Turova, Alexander Nesmelov, Andrey Kravets, Eduardo Shugaev-Mendosa, Nikita Kotlov
• 2438 · PDF 发现用于预测HRR驱动实体瘤治疗反应的循环蛋白质组学生物标志物 Discovery of predictive circulating proteomic biomarkers for therapy response in HRR-driven solid tumors Anamarija Pfeiffer, Wouter van Bergen, Martin Mehnert, Polina Shichkova, Vanessa Bühlmann, Amaury Lachaud, Yuehan Feng, Takayuki Yoshino, Norio Nonomura, Taigo Kato
• 2439 · PDF 利用炎症细胞因子谱和NCT04267081试验队列临床数据对急性髓系白血病中venetoclax/azacitidine治疗反应进行预测建模 Predictive modeling of venetoclax/azacitidine response in acute myeloid leukemia using inflammatory cytokine profiling and clinical data from the NCT04267081 trial cohort Ankita Srivastava, Bahar Tercan, David L. Gibbs, Heikki Kuusanmäki, Mika Kontro, Caroline A. Heckman, Guangrong Qin
• 2440 · PDF 单细胞MRD分析识别CXCR4高表达AML为对Motixafortide CXCR4抑制有反应的人群 Single-cell MRD profiling identifies CXCR4-high AML as a responder population to CXCR4 inhibition with Motixafortide Enise Ceran, Sonia Jaramillo-Segura, Anne Kahtrin Merbach, Christian Rohde, Robert Durruthy-Durruthy, Adam Sciambi, Marc Arribas-Layton, Michelle Lotze, Maxi Wass, Kathrin Rieger, Mathias Hänel, Regina Herbst, Christoph Röllig, Edgar Jost, Richard Schlenk, Katharina Götze, Marina Scheller, Marion Subklewe, Simone Kowoll, Jörg Steighardt, Bayram Edemir, Lutz P. Müller, Irit Glicko-Kabir, Abi Vainstein-Haras, Cora Gromann, Ella Sorani, Shaul Kadosh, Andreas Wienke, Claudia Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow
• 2441 · PDF KRAS突变癌症中的myCAF与ECM格局：利用液体生物标志物追踪KRAS诱导的纤维化和KRAS抑制剂疗效 The myCAF and ECM landscape in KRAS-mutated cancer: Utilizing liquid biomarkers to track KRAS-induced fibrosis and KRAS inhibitor efficacy Martin Birkmose Rasmussen, Rasmus Sund Pedersen, Nicholas Willumsen, Morten Karsdal
• 2442 · PDF 基线单细胞质量分布与套细胞淋巴瘤对acalabrutinib、venetoclax和obinutuzumab的临床反应相关 Baseline single-cell mass distributions correlate with clinical response to acalabrutinib, venetoclax, and obinutuzumab in mantle cell lymphoma Mingzeng Zhang, Ye Zhang, Lydie Debaize, Grace Chen, Sona Baghiyan, Shogo Miura, Nezha Senhaji, Juniper Mai, Clare Phinney, Alexa Batingana, Jenalyn Weekes, Salah Abdulkarim, Haocheng Wang, Svitlana Tyekucheva, Jerome Ritz, Christine E. Ryan, Austin I. Kim, Scott R. Manalis, Mark A. Murakami
• 2443 · PDF 泰国尿液农药生物标志物与肝病风险：一个基于机器学习的风险预测模型 Urinary pesticide biomarkers and liver disease risk in Thailand: A machine-learning-based risk-prediction model Daxeshkumar P. Patel, Christopher Loffredo, Majda Haznadar, Mohammed Khan, Amelia Parker, Benjarath Pupacdi, Siritida Rabibhadana, Panida Navasumrit, Nirush Lertprasertsuke, Anon Chotirosniramit, Chawalit Pairojkul, Vor Luvira, Ake Pugkhem, Wattana Sukeepaisarnjaroen, Teerapat Ungtrakul, Thaniya Sricharunrat, Kannika Phornphutkul, Frank J. Gonzalez, Anuradha Budhu, Chulabhorn Mahidol, Xin Wei Wang, Mathuros Ruchirawat, Curtis C. Harris, TIGER-LC Consortium
• 2444 · PDF PD-1检查点抑制剂反应的多智能体增强分析 Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response Ada Shaw, Christina Vivelo, Nicholas Dana, Chetan Sood, Michelle Garred, Aqib Hasnain, Shara Balakrishnan, Vivek Adarsh, Hinco Gierman, Erika von Euw
• 2445 · PDF LAPNET-01：一项评估NP137（一种上皮-间质转化抑制剂）联合mFOLFIRINOX一线治疗局部晚期胰腺导管腺癌的1b期研究的转化研究结果 LAPNET-01: Translational results of a Phase 1b evaluating NP137, an inhibitor of the epithelial-to-mesenchymal transition in combination with mFOLFIRINOX for the first-line treatment of locally advanced pancreatic ductal adenocarcinoma Gaël Roth, Pascal Artru, Olivier Bouche, Marc Manceau, Nicolas Williet, Julien Ghelfi, Anthony Turpin, Astrid Lièvre, Jean Frederic Blanc, Camille Evrard, Jean Baptiste Bachet, Pauline Parent, Matthieu Roustit, Hector Hernandez-Vargas, Elise Georges, Sébastien Hazard, Benjamin Ducarouge, Agnès Bernet, Patrick Mehlen
• 2446 · PDF 高PRMT5表达与非小细胞肺癌免疫浸润减少及免疫检查点抑制剂疗效较差相关 High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer Natalie Vokes, Stamatina Fragkogianni, Pooja A. Shah, Santiago G. Trevino, Konstantinos Leventakos, Lei Deng, Matthew Lee, Tali Azenkot, KAYLA LAYNG, JACOB MERCER, Jyoti Patel, Jordi Rodon Ahnert
• 2447 · PDF 基于表观基因组液体活检的胚系BRCA相关PDAC患者铂类和PARP抑制剂应答生物标志物：一项试点研究 Epigenomic liquid biopsy-based biomarkers of platinum and PARP inhibitor response in patients with germ line BRCA-associated PDAC: A pilot study Maria Raitses-Gurevich, Gulfem Guler, Yuhong Ning, Ceyda Coruh, Micah Collins, Shimul Chowdhury, Samuel Levy, Talia Golan
• 2448 · PDF 体细胞DDR突变作为转移性胰腺癌铂类获益的潜在预测性生物标志物 Somatic DDR mutations as potential predictive biomarkers of platinum benefit in metastatic pancreatic cancer Ethan L. Low, Aakash Shah, Eunji Jo, Aliya Lackan, Susan Hilsenbeck, Benjamin L. Musher
• 2449 · PDF 液体活检与实体组织基因组分析在预测晚期NSCLC化疗-免疫治疗获益中的比较 Comparison of liquid versus solid tissue genomic profiling for the prediction of chemo-immunotherapy benefit in advanced NSCLC Charu Aggarwal, Prashant Nair, Anagha Jenu, Poornachandra G, Ansu Kumar, Swati Khandelwal, Jyoti Chauhan, Susheel George, Neelsh Lunkad, Vijayashree PS, Nagendra Prasad, Shweta Kapoor, Drew Watson, James Wingrove, Tejas Patil
• 2450 · PDF 瘤周脂肪组织作为HNSCC免疫治疗应答的预后影像学生物标志物 Peritumoral adipose tissue as a prognostic imaging biomarker for immunotherapy response in HNSCC Kyle Harris, Nazila Godfrey, Dalia El-Gamal, Shesh Rai, Jianmin Pan, Brady Williamson, Trisha Wise-Draper
• 2451 · PDF 通过tCAM-seq实现胰腺癌化疗预测和突变检测的双功能平台 Dual-function platform for chemotherapy prediction and mutation detection in pancreatic cancer by t CAM-seq Arturo Orlacchio, Erik Ladewig, Adrienne K. Chandra, Anwesha Dhara, Sharon M. James, Steven D. Leach, Kenneth H. Yu, Surajit Dhara
• 2452 · PDF 蛋白质组学衰老生物标志物可预测免疫治疗肿瘤的生存期 Proteomic aging biomarkers predict survival in immunotherapy-treated tumors Michal Harel, Coren Lahav, Yehonatan Elon, M. Austin Argentieri, Surbhi Singhal, Adam P. Dicker
• 2453 · PDF 丙戊酸增强局部晚期直肠癌的免疫重编程：来自 V-shoRT-R3 试验的见解 Valproic acid enhances immune reprogramming in locally advanced rectal cancer: Insights from the VshoRTR3 trial Maria Serena Roca, Elena Di Gennaro, Federica Iannelli, Alfonso De Stefano, Carmen Romano, Francesca Collina, Cristina Testa, Rossella De Cecio, Palmina Bagnara, Susan Costantini, Roberto De Gregorio, Sean Houghton, Shauna Lee Houlihan, Dario Righelli, Andrea Sboner, Alicia Alonso, Antonio Avallone, Alfredo Budillon
• 2454 · PDF 药物反应预测因子（DRP®）与在 II 期试验中每日两次接受 2X-121/司替尼帕利（stenoparib）治疗的晚期、复发性卵巢癌患者总生存期的提高相关（NCT03878849） A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X-121/ Stenoparib (NCT03878849) Steen Knudsen, Annette Nielsen, Thomas Jensen, Peter Gimsing, Anker Hansen, Mogens Winkel Madsen, Michele Gargano, Jose Iglesias, Fernanda Musa, Kathleen N. Moore, Jeremy Graff
• 2456 · PDF 分析抗体-药物偶联物靶点在纤维板层型肝细胞癌中的表达 Profiling the expression of antibody-drug conjugates in fibrolamellar hepatocellular carcinoma Waqar Arif, Elsa Hallab, Franshisca Hayek, Howard Liu Li, Mari Nakazawa, Mark E. Furth, Andrew S. Liss, Patricia Cogswell, Ezra G. Baraban, Jacqueline Birkness-Gartman, Marina Baretti, Robert A. Anders, Mark Yarchoan

在会议检索中浏览本分会场